戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 is effect was blocked by the HRH1 antagonist pyrilamine.
2 dilatation was unaffected in the presence of pyrilamine.
3 P combined with 10 mm L-NAME plus 500 microm pyrilamine.
4 of L-NAME and the combination of L-NAME plus pyrilamine.
5 e, and the H1 histamine receptor antagonist, pyrilamine.
6                   The H1 receptor antagonist pyrilamine (10 microM) blocked activation of ICl(Ca) and
7 10 microM) and blocked by the H1 antagonists pyrilamine (100 nM) or diphenhydramine (100 nM).
8 eceived substance P combined with 500 microm pyrilamine, an H1 receptor antagonist.
9                                              Pyrilamine, an H1R antagonist, blocked EAE, and the plat
10 of H1 and H2 histamine receptor antagonists (pyrilamine and famotidine, respectively) greatly diminis
11                      The oral antihistamines pyrilamine and ranitidine were administered during toler
12 d the histamine 1 and 2 receptor antagonists pyrilamine and ranitidine, respectively, did not signifi
13 duced by histamine was inhibited by both H1 (pyrilamine) and H3 (thioperamide) but not H2 (ranitidine
14 In the H1 antagonist studies, CVC in l-NAME, pyrilamine, and combined l-NAME plus pyrilamine sites wa
15 n or celecoxib (cyclo-oxygenase inhibitors), pyrilamine, aprepitant (a neurokinin 1 receptor antagoni
16 istamine H1 antagonists, diphenhydramine and pyrilamine, at neurotensin (NT)-mediated hypothermia and
17 ment with histamine receptor H(1) antagonist pyrilamine blocked the increased sensory neuron excitabi
18      The histamine H(1)-receptor antagonist, pyrilamine, blocked the effects of 5 muM histamine when
19                      Although the effects of pyrilamine, cromolyn, or aprepitant on ET-induced vascul
20 the much more potent histamine H1 antagonist pyrilamine did not affect antinociception mediated by NT
21       Noteworthy, the H1 receptor antagonist pyrilamine disrupted IA memory retrieval in rats, thus s
22 athing slices in medium containing 10 microM pyrilamine (H1 antagonist) blocked this stimulation-indu
23 systemically-administered antagonists of H1 (pyrilamine), H2 (zolantidine), H3 (GT-2016), or opioid (
24         Site 4 was perfused with l-NAME plus pyrilamine maleate or l-NAME plus cimetidine.
25 3 was perfused with either the H1 antagonist pyrilamine maleate or the H2 antagonist cimetidine.
26        Schild plot analysis of the effect of pyrilamine on the histamine-induced inward current revea
27 tes were significantly reduced compared with pyrilamine only sites (P < 0.05) but no significant diff
28       In vivo, treatment with antihistamines pyrilamine or cimetidine decreased lung weight and sever
29 acin), agents that interfere with histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spa
30           Oral antihistamine treatments with pyrilamine or ranitidine did not impair tolerance and ne
31 inistering either an H1 receptor antagonist (pyrilamine) or an H2 receptor antagonist (cimetidine) de
32 1 receptor antagonist), or indomethacin with pyrilamine significantly reduced vascular leakage associ
33 l-NAME, pyrilamine, and combined l-NAME plus pyrilamine sites was significantly reduced compared with
34          The l-NAME and combined l-NAME plus pyrilamine sites were significantly reduced compared wit
35 en the L-NAME-only sites and the L-NAME plus pyrilamine sites.